Research & Development
ImmunoMet Therapeutics elects Dr Revati Shreeniwas as CMO
27 July 2021 -

Biotechnology company ImmunoMet Therapeutics Inc revealed on Monday the appointment of Dr Revati Shreeniwas as its chief medical officer.

As head of the medial department, Dr Shreeniwas will manage the clinical development programme for the company's lead investigational product Protein Complex 1 (PC1) inhibitor candidate, IM156, for idiopathic pulmonary fibrosis (IPF) and oncology indications.

Recently, Dr Shreeniwas has served on the faculty of Stanford University and Columbia Presbyterian Medical Center.

Previously, Dr Shreeniwas designed and implemented more than 50 US and international (Phase 1-4) clinical trials and been the clinical lead for regulatory interactions with the FDA and EMA.



Related Headlines